Intravitreal Bevacizumab (Avastin) Treatment of Choroidal Neovascularization in Patients with Angioid Streaks
- Torsten W Wiegand (twwiegand{at}eyeboston.com),
- Adam H Rogers (arogers1{at}tuftsmedicalcenter.org),
- Frank McCabe,
- Elias Reichel,
- Jay S Duker
- New England Eye Center / Ophthalmic Consultants of Boston, United States
- New England Eye Center, United States
- New England Eye Center / Vitreo-Retinal Associates of Worcester, United States
- New England Eye Center, United States
- New England Eye Center, United States
- Published Online First 29 October 2008
Abstract
Objective: To evaluate the safety and efficacy of intravitreal bevacizumab (Avastin) as treatment for choroidal neovascularization (CNV) associated with angioid streaks.
Methods: A non-randomized, interventional case series conducted on eyes with subfoveal CNV associated with angioid streaks. Intravitreal bevacizumab (1.25 mg in 0.05 ml) was injected into nine eyes of six patients between August 2005 and December 2007. Treatment efficacy was assessed based on pre- and post-treatment visual acuity and optical coherence tomography (OCT).
Results: With a mean follow-up of 19 months (range, 10 to 28 months) best corrected visual acuity improved by three or more lines in four eyes (44.4%), remained within two lines of baseline in four eyes (44.4%), and decreased by three or more lines in one eye (11.1%). Central foveal thickness (CFT) measured by OCT decreased an average of 67.7 µm (range, +11 to -175 µm) with an average improvement in standardized change in macular thickening of 46.6 % (range -12 % to + 84.5 %). No injection-related complications or drug-related side effects were observed.
Conclusions: Intravitreal bevazicumab for the treatment of subfoveal CNV secondary to angioid streaks mildly reduced central foveal thickness with a trend toward stabilization of visual acuity. Additional follow-up and a larger patient cohort are needed to evaluate the long term effects of this treatment.
